Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Santen SAS
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Males or females 18 years of age or greater.

• At baseline, moderate to severe dry eye condition persisting despite conventional management.

Exclusion Criteria:

• Presence or history of any systemic or ocular disorder or condition, including ocular surgery, trauma or disease that could possibly interfere with the interpretation of study results.

• Any relevant ocular anomaly interfering with the ocular surface, including post radiation keratitis, Stevens-Johnson syndrome, corneal ulcer history or concomitant corneal ulcer of infectious origin, etc.

• Any other ocular diseases requiring topical ocular treatment during the study period.

• Patient who has participated in a clinical trial with a new active substance during the past month before study entry.

• Participation in another clinical study at the same time as the present study.